Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02297100 · ClinicalTrials.gov registry record · Phase 4
Intravesicular Onabotulinumtoxin A in Interstitial Cystitis
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 27
- Enrollment target
NCT02297100 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 27 participants.
The verdict
NCT02297100, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this research study is to identify the optimal usage of Onabotulinumtoxin A in interstitial cystitis. Onabotulinumtoxin A, more commonly known by the trade name Botox®, is a medication that comes from the bacteria Clostridium botulinum. It works by blocking the release of the neurotransmitter acetylcholine(a chemical messenger that carries signals between nerve cells and other cells in the body). Blocking that neurotransmitter results in decreased muscle activity.
Interventions
- DRUG Onabotulinumtoxin A
- PROCEDURE injections upper aspect of trigone of urinary bladder
- PROCEDURE injections on posterior bladder wall excluding the trigone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-01-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02297100
The ClinicalTrials.gov registry entry for NCT02297100 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Onabotulinumtoxin A is the first listed.
NCT02297100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02297100 about?
NCT02297100 is a clinical study titled "Intravesicular Onabotulinumtoxin A in Interstitial Cystitis". The purpose of this research study is to identify the optimal usage of Onabotulinumtoxin A in interstitial cystitis. Onabotulinumtoxin A, more commonly known by the trade name Botox®, is a medication that comes from the bacteria Clostridium botulinum. It works by blocking the release of the neurotra...
What is the current status of trial NCT02297100?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 27 participants. The study started on 2014-12. Estimated completion is 2018-01-10.
What interventions are being tested in trial NCT02297100?
The interventions under investigation include: Onabotulinumtoxin A (DRUG), injections upper aspect of trigone of urinary bladder (PROCEDURE), injections on posterior bladder wall excluding the trigone (PROCEDURE).
Who is sponsoring clinical trial NCT02297100?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.